Structure-based design, synthesis, and pharmacological evaluation of 3-(Aminoalkyl)-5-fluoroindoles as myeloperoxidase inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 24, 2010, Pages 8747-8759

  Soubhye, Jalal ^a   Prévost, Martine ^a   Van Antwerpen, Pierre ^a   Zouaoui Boudjeltia, Karim ^a   Rousseau, Alexandre ^a   Furtmüller, Paul G ^b   Obinger, Christian ^b   Vanhaeverbeek, Michel ^a   Ducobu, Jean ^a   Nève, Jean ^a   Gelbcke, Michel ^a   Dufrasne, François ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUOROTRYPTAMINE; ALKYL GROUP; AMINE; APOLIPOPROTEIN B100; FLUORINE DERIVATIVE; INDOLE DERIVATIVE; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXIDASE; TAURINE;

ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CELL SURFACE; CHLORINATION; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME MECHANISM; HALOGENATION; IN VITRO STUDY; INFLAMMATION; INTIMA; LIPID OXIDATION; MOLECULAR DOCKING; OXIDATION REDUCTION REACTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; HALOGENATION; INDOLES; KINETICS; LIPOPROTEINS, LDL; MODELS, MOLECULAR; OXIDATION-REDUCTION; PEROXIDASE; PROTEIN BINDING; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TAURINE; THERMODYNAMICS;

EID: 78650365994     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1009988     Document Type: Article

References (59)

1. Klebanoff, S. J. Myeloperoxidase: Friend and foe J. Leukocyte Biol. 2005, 77, 598-562
2. Nicholls, S. J.; Hazen, S. L. Myeloperoxidase and cardiovascular disease Arterioscler. Thromb. Vasc. Biol. 2005, 25, 1102-1111
3. Nicholls, S. J.; Hazen, S. L. Myeloperoxidase, modified lipoproteins, and atherogenesis J. Lipid Res. 2009, Suppl.) S346-S351
4. Green, P. S.; Mendez, A. J.; Jacob, J. S.; Crowley, J. R.; Growdon, W.; Hyman, B. T.; Heinecke, J. W. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease J. Neurochem. 2004, 90, 724-733
5. Maruyama, Y.; Lindholm, B.; Stenvinkel, P. Inflammation and oxidative stress in ESRD - the role of myeloperoxidase J. Nephrol. 2004, 17, S72-S76
6. Kettle, A. J.; Chan, T.; Osberg, I.; Senthilmohan, R.; Chapman, A. L. P.; Mocatta, T. J.; Wagener, J. S. Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis Am. J. Resp. Crit. Care Med. 2004, 170, 1317-1323
7. Minohara, M.; Matsuoka, T.; Li, W.; Osoegawa, M.; Ishizu, T.; Ohyagi, Y.; Kira, J.-I. Upregulation of myeloperoxidase in patients with opticospinal multiple sclerosis: positive correlation with disease severity J. Neuroimmunol. 2006, 178, 156-160
8. Taguchi, J.; Miyazaki, Y.; Tsutsumi, C.; Sawayama, Y.; Ando, K.; Tsushima, H.; Fukushima, T.; Hata, T.; Yoshida, S.; Kuriyama, K. Expression of the myeloperoxidase gene in AC133 positive leukemia cells relates to the prognosis of acute myeloid leukemia Leukocyte Res. 2006, 30, 1105-1112
9. Lefkowitz, D. L.; Lefkowitz, S. S. Microglia and myeloperoxidase: a deadly partnership in neurodegenerative disease Free Radic. Biol. Med. 2008, 45, 726-731
10. Gray, E.; Thomas, T. L.; Betmouni, S.; Scolding, N.; Love, S. Elevated myeloperoxidase activity in white matter in multiple sclerosis Neurosci. Lett. 2008, 444, 195-198
11. Itabe, H. Oxidative modification of LDL: its pathological role in atherosclerosis Clinic. Rev. Allergy Immunol. 2009, 37, 4-11
12. Zouaoui-Boudjeltia, K.; Legssyer, I.; Van Antwerpen, P.; Lema Kisoka, R.; Babar, S.; Moguilevsky, N.; Delree, P.; Ducobu, J.; Remacle, C.; Vanhaeverbeek, M.; Brohee, D. Triggering of inflammatory response by myeloperoxidase-oxidized LDL Biochem. Cell Biol. 2006, 84, 805-812
13. Shao, B. H.; Cavigiolio, G.; Brot, N.; Oda, M. N.; Heinecke, J. W. Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-1 Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 12224-12229
14. Chantepie, S.; Malle, E.; Sattler, W.; Chapman, M. J.; Kontush, A. Distinct HDL subclasses present similar intrinsic susceptibility to oxidation by HOCl Arch. Biochem. Biophys. 2009, 487, 28-35
15. Malle, E.; Furtmüller, P. G.; Sattler, W.; Obinger, C. Myeloperoxidase: a target for new drug development? Br. J. Pharmacol. 2007, 152, 838-854
16. Van Antwerpen, P.; Prévost, M.; Zouaoui-Boudjeltia, K.; Babar, S.; Legssyer, I.; Moreau, P.; Moguilevsky, N.; Vanhaeverbeek, M.; Ducobu, J.; Nève, J.; Dufrasne, F. Conception of myeloperoxidase inhibitors derived from flufenamic acid by computational docking and structure modification Bioorg. Med. Chem. 2008, 16, 1702-1720
17. Tiden, A.-K.; Weistrand, C. Preparation of 1-(2-hydroxyethyl)-2-thioxo-1, 2,3,5-tetrahydropyrrolo[3,2- d ]pyrimidin-4-one as a myeloperoxidase (MPO) inhibitor. PCT Int. Appl. WO2007142577, 2007.
18. Tiden, A.-K. Preparation of 2-thioxanthines as myeloperoxidase (MPO) inhibitors. PCT Int. Appl. WO2007142576, 2007.
19. Tiden, A.-K.; Viklund, J. Preparation of thioxanthines as inhibitors of myeloperoxidase (MPO). PCT Int. Appl. WO2007120098, 2007.
20. Boegevig, A.; Lo-Alfredsson, Y.; Pivonka, D.; Tiden, A.-K. Preparation of pyrrolo[3,2- d ]pyrimidin-4-one derivatives as MPO enzyme inhibitors. PCT Int. Appl. WO2006062465, 2006.
21. Tiden, A.-K.; Turek, D.; Viklund, J. Preparation of triazole derivatives as myeloperoxidase inhibitors. PCT Int. Appl. WO2006046910, 2006.
22. Soyer, Z.; Bas, M.; Pabuccuoglu, A.; Pabuccuoglu, V. Synthesis of some 2(3 H)-benzoxazolone derivatives and their in vitro effects on human leukocyte myeloperoxidase activity Arch. Pharm. 2005, 338, 405-410
23. Svensson, M.; Tiden, A.-K.; Turek, D. Preparation of [1,2,4]triazole-3- thiones as inhibitors of myeloperoxidase for the treatment of neuroinflammatory disorders. PCT Int. Appl. WO2004096781, 2004.
24. Hanson, S.; Nordvall, G.; Tiden, A.-K. Preparation of xanthinethione derivatives as myeloperoxidase inhibitors. PCT Int. Appl. WO2003089430, 2003.
25. Tanimoto, T.; Tanaka, I.; Nakajima, M. New myeloperoxidase inhibitors and their manufacture with Penicillium. Jpn. Kokai Tokkyo Koho JP2001131133, 2001.
26. McLean, D. B.; Thompson, D. D. Pharmaceutical compositions containing myeloperoxidase inhibitors. U.S. Pat. Appl. US5719190, 1998.
27. Glasebrook, A. L. 2-Phenyl-3-azoylbenzothiophenes for inhibition of myeloperoxidase activity. Eur. Pat. Appl. EP664125, 1995.
28. Egan, R. W.; Hagmann, W. K.; Gale, P. H. Naphthalenes as inhibitors of myeloperoxidase: direct and indirect mechanisms of inhibition Agents Actions 1990, 29, 266-276
29. Van Antwerpen, P.; Dufrasne, F.; Lequeux, M.; Zouaoui-Boudjeltia, K.; Lessgyer, I.; Babar, S.; Moreau, P.; Moguilevsky, N.; Vanhaeverbeek, M.; Ducobu, J.; Nève, J. Inhibition of the myeloperoxidase chlorinating activity by nonsteroidal anti-inflammatory drug flufenamic acid and its 5-chloro-derivative directly interact with a recombinant human myeloperoxidase to inhibit the synthesis of hypochlorous acid Eur. J. Pharmacol. 2007, 570, 235-243
30. 2/chloride system to inhibit LDL oxidation Biochem. Biophys. Res. Commun. 2005, 337, 82-88
31. Jantschko, W.; Furtmüller, G. P.; Zederbauer, M.; Neugschwandtner, K.; Lehner, I.; Jakopitsch, C.; Arnhold, J.; Obinger, C. Exploitation of the unusual thermodynamic properties of human myeloperoxidase in inhibitor design Biochem. Pharmacol. 2005, 69, 1149-1157
32. Ximenes, V. F.; Paino, I. M. M.; de Faria-Oliveira, O. M. M.; da Fonseca, L. M.; Brunetti, I. L. Indole ring oxidation by activated leukocytes prevents the production of hypochlorous acid Braz. J. Med. Biol. Res. 2005, 38, 1575-1583
33. Galijasevic, S.; Abdulhamid, I.; Abu-Soud, H. M. Melatonin Is a Potent Inhibitor for Myeloperoxidase Biochemistry 2008, 47 (8) 2668-2677
34. Lu, T.; Galijasevic, S.; Abdulhamid, I.; Abu-Soud, H. M. Analysis of the mechanism by which melatonin inhibits human eosinophil peroxidase Br. J. Pharmacol. 2008, 154 (6) 1308-1317
35. Adrien, B.; Carmela, G.; Sylvain, P.; Yann, D.; de Sousa, R. A.; Valery, L.; Thierry, C.; Frederi, D. C.; Isabelle, A.; Thierry, M. Discovery and Refinement of a New Structural Class of Potent Peptide Deformylase Inhibitors J. Med. Chem. 2007, 50, 10-20
36. Nishimura, S. Handbook of Heterogeneous Catalytic Hydrogenation for Organic Synthesis; J. Wiley & Sons, Inc: New York, 2001; pp 290-301.
37. Lindquist, C.; Ersoy, O.; Somfai, P. Parallel synthesis of an indol-based library via an iterative Mannich reaction sequence Tetrahedron 2006, 62, 3439-3445
38. Campos, K.; Woo, J.; Lee, S.; Tillyer, R. A general synthesis of substituted indoles from cyclic enol ethers and enol lactones Org. Lett. 2004, 6, 79-82
39. Dufrasne, F.; Nève, J. Synthesis of 1,2-diamino-1-phenylpropane diastereoisomers from u- N -trifluoroacetyl-2-amino-1-phenylpropan-1-ol Monatsh. Chem. 2005, 163, 739-746
40. Stevenson, R.; Sant Milid, P.; Haider, R.; Hilmi, A.; Al Farham, E. Method for making substituted indole. PCT Int. Appl. WO9959970, 1999.
41. Hatzenbuhler, N. T.; Evrard, D. A.; Mewshaw, R. E.; Zhou, D.; Shah, U. S.; Inghrim, J. A.; Lenicek, S. E.; Baudy, R. B.; Butera, J. A.; Sabb, A. L.; Failli, A. A.; Ramamoorthy, P. S. A preparation of 3-aminochroman and 2-aminotetralin derivatives, useful in the treatment of serotonin-mediated disorders. PCT Int. Appl. WO2005012291, 2005.
42. Hall, H.; Gisler, M. A Simple Method for Converting Nitriles to Amides. Hydrolysis with potassium hydroxide in tert -butyl alcohol J. Org. Chem. 1976, 41, 3769-3770
43. Mewshaw, R. E.; Zhou, D.; Zhou, P.; Shi, X.; Hornby, G.; Spangler, T.; Scerni, R.; Smith, D.; Schechter, L. E.; Andree, T. H. Studies toward the Discovery of the Next Generation of Antidepressants. 3. Dual 5-HT1A and Serotonin Transporter Affinity within a Class of N - Aryloxyethylindoleylalkylamines J. Med. Chem. 2004, 47, 3823-3842
44. 2O/NaI system in acetonitrile J. Org. Chem. 2000, 65, 2830-2833
45. Van der Mee, L.; Helmich, F.; De Bruijn, R.; Vekemans, J. A. J. M.; Palmans, A. R. A.; Meijer, E. W. Investigation of Lipase-Catalyzed Ring-Opening Polymerizations of Lactones with Various Ring Sizes: Kinetic Evaluation Macromolecules 2006, 39, 5021-5027
46. Van Antwerpen, P.; Moreau, P.; Zouaoui-Boudjeltia, K.; Babar, S.; Dufrasne, F.; Moguilevsky, N.; Vanhaeverbeek, M.; Ducobu, J.; Nève, J. Development and validation of screening procedure for the assessment of inhibition using a recombinant enzyme Talanta 2007, 75, 503-510
47. Kettle, A. J.; Winterbourn, C. C. Superoxide modulates the activity of myeloperoxidase and optimizes the production of hypochlorous acid Biochem. J. 1988, 252, 529-536
48. Carr, A. C.; Myzak, M. C.; Stocker, R.; McCall, M. R.; Frei, B. Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis FEBS Lett. 2000, 487, 176-180
49. Furtmüller, P. G.; Zederbauer, M.; Jantschko, W.; Helm, J.; Bogner, M.; Jakopitsch, C.; Obinger, C. Active site structure and catalytic mechanisms of human peroxidases Arch. Biochem. Biophys. 2006, 445, 199-213
50. Blair-Johnson, M.; Fiedler, T.; Fenna, R. Human myeloperoxidase: structure of a cyanide complex and its interaction with bromide and thiocyanate substrates at 1.9 Å resolution Biochemistry 2001, 40, 13990-13997
51. Sadowski, J.; Gasteiger, J. From atoms and bonds to three-dimensional atomic coordinates: automatic model builders Chem. Rev. 1993, 93, 2567-2581
52. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 2004, 47, 1739-1749
53. Shelley, J. C.; Cholleti, A.; Frye, L. L.; Greenwood, J. R.; Timlin, M. R.; Uchimaya, M. Epik: a software program for p K (a) prediction and protonation state generation for drug-like molecules J. Comput.-Aided Mol. Des. 2007, 21, 681-691
54. Smid, P.; Coolen, H. K. A. C.; Keizer, H. G.; Van Hes, R.; De Moes, J.; Den Hartog, A. P.; Stork, B.; Plekkenpol, R. H.; Niemann, L. C.; Stroomer, C. N. J.; Tulp, M. Th. M.; Van Stuivenberg, H. H.; McCreary, A. C.; Hesselink, M. B.; Herremans, A. H. J.; Kruse, C. G. Synthesis, Structure-Activity Relationships, and Biological Properties of 1-Heteroaryl-4-[ω-(1 H -indol-3-yl)alkyl] piperazines, Novel Potential Antipsychotics Combining Potent Dopamine D2 Receptor Antagonism with Potent Serotonin Reuptake Inhibition J. Med. Chem. 2005, 48, 6855-6869
55. Mewshaw, R. E.; Zhou, D.; Zhou, P.; Shi, X.; Hornby, G.; Spangler, T.; Scerni, R.; Smith, D.; Schechter, L. E.; Andree, T. H. Studies toward the Discovery of the Next Generation of Antidepressants. 3. Dual 5-HT1A and Serotonin Transporter Affinity within a Class of N - Aryloxyethylindolylalkylamines J. Med. Chem. 2004, 47, 3823-3842
56. Hewson, W. D.; Hager, L. P. Mechanism of the chlorination reaction catalyzed by horseradish peroxidase with chlorite J. Biol. Chem. 1979, 254, 3175-3181
57. Havel, R. J.; Eder, H. A.; Bragdon, J. H. Distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum J. Clin. Invest. 1955, 34, 1345-1353
58. Moguilevsky, N.; Zouaoui-Boudjeltia, Z.; Babar, S.; Delrée, P.; Legssyer, I.; Carpentier, Y.; Vanhaeverbeek, M.; Ducobu, J. Monoclonal antibodies against LDL progressively oxidized by myeloperoxidase react with ApoB-100 protein moiety and human atherosclerotic lesions Biochem. Biophys. Res. Commun. 2004, 323, 1223-1228
59. Furtmüller, P. G.; Burner, U.; Obinger, C. Reaction of human myeloperoxidase Compound I with chloride, bromide, iodide, and thiocyanate Biochemistry 1998, 37, 17923-17930